Evidence map›Paper›PMID 37261134›Full record

ArticleBreast care (Basel, Switzerland)2023

Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer.

Kerstin Rhiem, Silke Zachariae, Anke Waha, Sabine Grill, Anna Hester, Michael Golatta, Marion van Mackelenbergh, Tanja Fehm, Tanja Schlaiß, Tim Ripperger and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 1 country.

Kerstin RhiemCenter for Hereditary Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Silke ZachariaeInstitute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany.
Anke WahaCenter for Hereditary Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Sabine GrillDepartment of Gynecology and Center for Hereditary Breast and Ovarian Cancer, Klinikum Rechts der Isar, Technical University Munich (TUM), Munich, Germany.
Anna HesterDepartment of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Michael GolattaDepartment of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
Marion van MackelenberghDepartment Gynecology and Obstetrics, University Hospital Schleswig Holstein (UKSH) Campus Kiel, Kiel, Germany.
Tanja FehmDepartment of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Tanja SchlaißInstitute for Gynecology and Obstetrics and Center for Hereditary Breast and Ovarian Can-cer, Medical Faculty, University Hospital Würzburg, Würzburg, Germany.
Tim RippergerDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Susanne LedigInstitute of Human Genetics, University of Münster, Münster, Germany.
Cornelia MeiselDepartment of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany.
Dorothee SpeiserDepartment of Gynecology and Breast Centre, Centre for Hereditary Breast and Ovarian Cancer Charité, Charité University Hospital, Berlin, Germany.
Kristina VeselinovicDepartment of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Christopher SchröderInstitute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.
Isabell WitzelDepartment of Gynecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Julia GallwasDepartment of Gynecology and Obstetrics, University Medicine Göttingen, Göttingen, Germany.
Bernhard H F WeberInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Christine SolbachCenter for Hereditary Breast and Ovarian Cancer, University Hospital Frankfurt, Frankfurt, Germany.
Bariyhe AktasDepartment of Gynecology, University of Leipzig Medical Center, Leipzig, Germany.
Eric HahnenCenter for Hereditary Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Christoph EngelInstitute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany.
Rita SchmutzlerCenter for Hereditary Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
University Hospital Cologne · DELeipzig University · DECharité - Universitätsmedizin Berlin · DEDüsseldorf University Hospital · DEGerman Cancer Research Center · DEGoethe University Frankfurt · DEHeidelberg University · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DETUM Klinikum · DEUniversität Hamburg · DEUniversitätsklinikum Würzburg · DEUniversitätsmedizin Göttingen · DEUniversity Hospital Regensburg · DEUniversity Hospital Schleswig-Holstein · DEUniversity Hospital Ulm · DEUniversity of Münster · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: International guidelines recommend genetic testing for women with familial breast cancer at an expected prevalence of pathogenic germline variants (PVs) of at least 10%. In a study sample of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), we have previously shown that women with TNBC diagnosed before the age of 50 years but without a family history of breast or ovarian cancer (sTNBC) meet this criterion. The present study investigates the PV prevalence in Patients and Methods: In 1,600 women with sTNBC (median age at diagnosis: 41 years, range 19-78 years), we investigated the association between age at diagnosis and PV occurrence in cancer predisposition genes using logistic regression. Results: 260 sTNBC patients (16.2%) were found to have a PV in cancer predisposition genes ( Conclusion: Based on the data presented, we recommend genetic testing by gene panel analysis for sTNBC patients diagnosed before the age of 60 years. Due to the still uncertain estimate for women with sTNBC diagnosed above the age of 60 years, further studies are needed.

Indexed as

BRCA1BRCA2, triple negativeBreast cancerHereditary breast and ovarian cancer

Identifiers

PMID37261134
PMCPMC10228253
OpenAlexW4313614006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.